UBS Group’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-101,391
| Closed | -$39K | – | 8702 |
|
|
2020
Q1 | $39K | Buy |
101,391
+77,385
| +322% | +$28K | ﹤0.01% | 6032 |
|
|
2019
Q4 | $10K | Buy |
24,006
+23,406
| +3,901% | +$38.9K | ﹤0.01% | 7318 |
|
|
2019
Q3 | $1K | Sell |
600
-409
| -41% | -$828 | ﹤0.01% | 7914 |
|
|
2019
Q2 | $2K | Buy |
1,009
+409
| +68% | +$1.04K | ﹤0.01% | 7673 |
|
|
2019
Q1 | $2K | Hold |
600
| – | – | ﹤0.01% | 7493 |
|
|
2018
Q4 | $1K | Sell |
600
-4,815
| -89% | -$16K | ﹤0.01% | 7951 |
|
|
2018
Q3 | $21K | Buy |
5,415
+4,815
| +803% | +$21.2K | ﹤0.01% | 6782 |
|
|
2018
Q2 | $2K | Hold |
600
| – | – | ﹤0.01% | 7771 |
|
|
2018
Q1 | $1K | Hold |
600
| – | – | ﹤0.01% | 7709 |
|
|
2017
Q4 | $1K | Sell |
600
-1,562
| -72% | -$2.51K | ﹤0.01% | 7761 |
|
|
2017
Q3 | $4K | Buy |
2,162
+1,562
| +260% | +$5.31K | ﹤0.01% | 7343 |
|
|
2017
Q2 | $3K | Buy |
600
+172
| +40% | +$624 | ﹤0.01% | 7325 |
|
|
2017
Q1 | $1K | Sell |
428
-2,552
| -86% | -$7.53K | ﹤0.01% | 7508 |
|
|
2016
Q4 | $8K | Buy |
+2,980
| New | +$8.52K | ﹤0.01% | 7054 |
|
|
2016
Q1 | – | Sell |
-2,709
| Closed | -$22K | – | 8453 |
|
|
2015
Q4 | $22K | Buy |
2,709
+1,848
| +215% | +$15.4K | ﹤0.01% | 6674 |
|
|
2015
Q3 | $7K | Sell |
861
-6,988
| -89% | -$64.4K | ﹤0.01% | 7535 |
|
|
2015
Q2 | $74K | Buy |
7,849
+3,606
| +85% | +$33.6K | ﹤0.01% | 5656 |
|
|
2015
Q1 | $39K | Buy |
4,243
+133
| +3% | +$1.27K | ﹤0.01% | 6288 |
|
|
2014
Q4 | $38K | Buy |
+4,110
| New | +$34.6K | ﹤0.01% | 6835 |
|
UBS Group's CORV Position: Q2 2020 in Review
UBS Group sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q2 2020, closing a stake of 101,391 shares — an estimated $39K sold.
UBS Group first reported a position in CORV in Q4 2014 and held it in 19 quarters. The position peaked at $74K in Q2 2015. 0 funds tracked by Wall St. Rank hold CORV as of Q2 2020.
- UBS Group reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q2 2020 after selling out during the quarter.
- UBS Group sold 101,391 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q2 2020, an estimated $39K.
- UBS Group first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q4 2014 and held it in 19 quarters.
- UBS Group's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $74K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q2 2020.
Based on UBS Group's 13F filing for Q2 2020, filed 31 Jul 2020.